Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R B Pedley

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|August 7, 2008
Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in miceJ A Violet, J L J Dearling, A J Green, et al.
Radiation Research|June 22, 2001
A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumorA A Flynn, A J Green, R B Pedley, et al.
International Journal of Radiation Oncology, Biology, Physics|February 16, 1999
A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft modelA A Flynn, A J Green, G M Boxer, et al.
Biochemical Pharmacology|June 1, 1990
Carboxypeptidase G2 and trimetrexate cause growth delay of human colonic cancer cells in vitroF Searle, K D Bagshawe, R B Pedley, et al.
British Journal of Cancer|November 27, 1999
Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragmentsJ L Casey, R B Pedley, D J King, et al.
Cancer Investigation|August 7, 2003
Higher dose and dose-rate in smaller tumors result in improved tumor controlA Mayer, E Tsiompanou, A A Flynn, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibodyA Mayer, K A Chester, J Bhatia, et al.
British Journal of Cancer|December 1, 1994
The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibodyR B Pedley, J A Boden, R Boden, et al.
British Journal of Cancer|February 12, 1998
Biodistribution of a radiolabelled monoclonal antibody NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancerD Ornadel, J A Ledermann, K Eagle, et al.
Anti-Cancer Drug Design|December 1, 1996
Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT)C J Springer, V Bavetsias, A L Jackman, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|August 7, 2008
Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in miceJ A Violet, J L J Dearling, A J Green, et al.
Radiation Research|June 22, 2001
A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumorA A Flynn, A J Green, R B Pedley, et al.
International Journal of Radiation Oncology, Biology, Physics|February 16, 1999
A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft modelA A Flynn, A J Green, G M Boxer, et al.
Biochemical Pharmacology|June 1, 1990
Carboxypeptidase G2 and trimetrexate cause growth delay of human colonic cancer cells in vitroF Searle, K D Bagshawe, R B Pedley, et al.
British Journal of Cancer|November 27, 1999
Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragmentsJ L Casey, R B Pedley, D J King, et al.
Cancer Investigation|August 7, 2003
Higher dose and dose-rate in smaller tumors result in improved tumor controlA Mayer, E Tsiompanou, A A Flynn, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibodyA Mayer, K A Chester, J Bhatia, et al.
British Journal of Cancer|December 1, 1994
The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibodyR B Pedley, J A Boden, R Boden, et al.
British Journal of Cancer|February 12, 1998
Biodistribution of a radiolabelled monoclonal antibody NY3D11 recognizing the neural cell adhesion molecule in tumour xenografts and patients with small-cell lung cancerD Ornadel, J A Ledermann, K Eagle, et al.
Anti-Cancer Drug Design|December 1, 1996
Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT)C J Springer, V Bavetsias, A L Jackman, et al.
Pageof 8